Core Viewpoint - The Xiamen University Affiliated Cardiovascular Hospital successfully performed the world's first cross-border robotic-assisted cardiac intervention surgery, demonstrating advanced medical technology and international collaboration [1] Group 1 - The surgery involved real-time collaboration between experts from China and France, with a communication transmission distance exceeding 10,000 kilometers [1] - The robotic catheter-based cardiac intervention system used in the surgery is independently developed in China and possesses complete intellectual property rights [1]

Core Insights - The successful implementation of the "Kai" microsurgery robot-assisted flap vascular anastomosis surgery at Wuxi Ninth People's Hospital marks a significant advancement in precision treatment in microsurgery within Jiangsu Province [1][6] - This operation demonstrates the hospital's commitment to integrating cutting-edge medical technology into clinical practice, enhancing patient care [6] Group 1: Surgical Procedure Details - The patient, Mr. Ran, suffered severe injuries from a workplace accident, requiring complex surgical intervention to repair multiple damaged structures in his right wrist [3] - The surgical team utilized the "Kai" robot to perform a free flap transfer from the left thigh to the right wrist, addressing the challenges of microvascular anastomosis that traditional methods struggle with due to physiological tremors [3][4] - The robot's 2mm seven-degree-of-freedom bionic arm allowed for enhanced precision, with the ability to control operation accuracy within 3-5 micrometers [4] Group 2: Technological and Institutional Impact - The successful surgery is a testament to the hospital's role as a regional medical center, focusing on patient-centered care and the application of advanced medical technologies [6] - Wuxi Ninth People's Hospital is the first in Jiangsu Province to apply the "Kai" microsurgery robot in clinical trials, filling a significant gap in the region and providing valuable experience for standardizing surgical procedures and training for local physicians [6]

Core Viewpoint - The company has initiated the first patient enrollment for the ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system, marking a significant milestone in its clinical trial process [1] Group 1: Clinical Trial Details - The clinical trial is a prospective, multi-center, randomized controlled, non-inferiority study aimed at evaluating the safety and efficacy of the ReachTactile robotic-assisted TAVR system and its disposable surgical kit [1] - The first successful treatment using the ReachTactile system was completed on September 17, 2025, by a team led by Academician Han Yaling at the Northern Theater General Hospital [1] Group 2: System Features and Innovations - The ReachTactile system is an internally developed robotic-assisted TAVR solution that offers innovative and cost-effective options for TAVR treatment [1] - Its modular and mobile design is compatible with traditional interventional catheterization rooms, allowing a cardiologist to operate multiple instruments with sub-millimeter precision [1] - The system features a force sensing mechanism that provides real-time tactile feedback, aiding in instrument navigation under complex vascular conditions [1] - The master-slave control layout effectively reduces the operator's radiation exposure and associated occupational health risks [1] - The Ethernet-based remote control functionality enables cross-regional surgical operations and training [1]

Group 1 - The company Peijia Medical-B (09996) has announced the enrollment of the first patient in the clinical trial for the ReachTactile robotic-assisted transcatheter aortic valve replacement (TAVR) system [1] - The first successful treatment using the ReachTactile system was completed on September 17, 2025, by a team led by Academician Han Yaling at the Northern Theater General Hospital, implanting a TaurusElite transcatheter aortic valve in a patient with severe aortic stenosis [1] - The clinical trial is a prospective, multi-center, randomized controlled, non-inferiority study aimed at evaluating the safety and efficacy of the ReachTactile robotic-assisted TAVR system and its disposable surgical kit [1] Group 2 - The ReachTactile system is an internally developed robotic-assisted TAVR solution that offers innovative and cost-effective options for TAVR treatment [1] - The system features a modular mobile design that fits traditional vascular intervention catheter rooms, allowing a cardiologist to operate multiple instruments with sub-millimeter precision [1] - The force sensing mechanism provides immediate tactile feedback, aiding in instrument navigation under complex vascular conditions, while the master-slave control layout effectively reduces radiation exposure risks for the operator [1]

Core Viewpoint - The company has successfully enrolled the first patient in the clinical trial for the ReachTactile™ robotic-assisted transcatheter aortic valve replacement (TAVR) system, marking a significant milestone in its development and potential market entry [1] Group 1: Clinical Trial Details - The clinical trial is a prospective, multi-center, randomized controlled, non-inferiority study aimed at evaluating the safety and efficacy of the ReachTactile robotic-assisted TAVR system and its disposable surgical kit [1] - The first patient treatment was successfully completed on September 17, 2025, by a team led by Academician Han Yaling at the Northern Theater Command General Hospital [1] Group 2: Product Features and Innovations - The ReachTactile system is an internally developed robotic-assisted TAVR solution that offers innovative and cost-effective options for TAVR treatment [1] - Its modular and mobile design is compatible with traditional interventional catheterization rooms, allowing a cardiologist to operate multiple devices with sub-millimeter precision [1] - The system features a force sensing mechanism that provides real-time tactile feedback, aiding in device navigation under complex vascular conditions [1] - The master-slave control layout effectively reduces radiation exposure risks for operators, enhancing occupational health safety [1] - The Ethernet-based remote control capability allows for cross-regional surgical operations and training [1]

Core Viewpoint - The company has successfully enrolled the first patient in the clinical trial for the ReachTactile™ robotic-assisted TAVR system, marking a significant milestone in its development and potential market entry [1][2]. Group 1: Clinical Trial Details - The clinical trial for the ReachTactile™ robotic-assisted TAVR system is a prospective, multi-center, randomized controlled, non-inferiority study aimed at evaluating the safety and efficacy of the system and its disposable surgical kit in TAVR procedures [1]. - The first patient treatment was successfully completed on September 17, 2025, by a team led by Academician Han Yaling at the Northern Theater Command General Hospital [1]. Group 2: Product Features and Innovations - ReachTactile™ is an internally developed robotic-assisted TAVR system that offers an innovative and cost-effective solution for TAVR treatment [2]. - The system features a modular design that is compatible with traditional interventional catheterization rooms, allowing a cardiologist to operate multiple instruments with sub-millimeter precision [2]. - It includes a force sensing mechanism that provides real-time tactile feedback, aiding in instrument navigation under complex vascular conditions [2]. - The system's master-slave control layout effectively reduces the operator's radiation exposure and associated occupational health risks [2]. - Additionally, the Ethernet-based remote control functionality enables cross-regional surgical operations and training [2].